Keytruda vs Ibrance
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
| US Keytruda | US Ibrance | |
|---|---|---|
| Generic name | pembrolizumab | palbociclib |
| Drug class | PD-1 Inhibitor (Immunotherapy) | CDK4/6 Inhibitor |
| Treats | Multiple cancers | HR+/HER2- breast cancer |
| Category | Oncology | Oncology |
| Manufacturer | Merck | Pfizer |
| Year approved | 2014 | 2015 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $260M | $80M |
| Common side effects | Immune-related side effects, Fatigue, Rash, Diarrhea | Low white blood cell count, Infections, Fatigue, Nausea |
Frequently asked questions
Is Keytruda or Ibrance better?
Neither is universally "better." Keytruda (pembrolizumab) and Ibrance (palbociclib) are both used for oncology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Keytruda and Ibrance?
Keytruda is a PD-1 Inhibitor (Immunotherapy) made by Merck, while Ibrance is a CDK4/6 Inhibitor made by Pfizer. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Keytruda has the larger estimated TV advertising budget of the two.